We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Global In Vitro Diagnostics Market to Reach USD 90 Billion by 2025

By LabMedica International staff writers
Posted on 07 Feb 2019
The global in vitro diagnostics market was valued at USD 55.00 billion in 2016 and is projected to grow at a healthy CAGR of 5.60% between 2017 and 2025 to reach USD 89.8 billion by the end of 2025. More...
The market growth will be driven by the rising prevalence of chronic diseases worldwide, an increase in the number of public and private diagnostic centers due to growing awareness of various diseases among the people, and an increasingly health conscious population who prefer early treatment. Additionally, the aggressive growth in the health sector and rapid technological advancements are helping to create better and more efficient products, thereby further aiding the market growth.

These are the latest findings of Transparency Market Research, (Albany, NY, USA), a global market intelligence company providing business information reports and services.

Increasing incidences of chronic diseases such as cancer, tuberculosis, diabetes, and cardiovascular diseases are likely to drive the growth of the global in vitro diagnostics market over the coming years. Additionally, a surge in the number of patients suffering from infectious diseases, such as sexually transmitted diseases (STDs), respiratory, and gastrointestinal, are expected to further boost the demand in the market. A sharp increase in cardiovascular diseases and diabetes, particularly in the developed countries, has helped the in vitro diagnostic market grow at a stupendous pace. Moreover, an increase in the geriatric population is also fueling market demand as the elderly people are more vulnerable to diseases due to their low immunity, thereby boosting the overall healthcare industry and resulting in the huge growth of the vitro diagnostic market.

The healthcare industry has been witnessing tremendous development and is expected to continue growing during the forecasts period on the back of the advent of personalized medicines and rise in the uptake of automated instruments. Earlier, in vitro diagnostics used to be performed only in labs, but can now be quickly and accurately carried out at home without the presence of any skilled professionals. One can test for pregnancy, blood glucose levels and even diseases such as HIV at home without visiting a diagnostic center, resulting in reduced hospital bills and increasing convenience. Such devices have gained immense popularity among the people due to their user-friendly nature, thus further boosting the growth of the in vitro diagnostics market. However, frequent regulatory changes and the lack of favorable reimbursement facilities for in vitro diagnostic are likely to hamper the market growth.

Currently, the global in vitro diagnostics market is highly competitive with a large number of players operating worldwide. The increasing emphasis of the key players on research and development, coupled with the introduction of new technology, is expected to support the market growth over the next few years. Additionally, increasing mergers and acquisition are likely to help the leading players maintain their position and increase market penetration in the coming years.

Related Links:
Transparency Market Research

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.